You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

Details for New Drug Application (NDA): 209022

✉ Email this page to a colleague

« Back to Dashboard

NDA 209022 describes XHANCE, which is a drug marketed by Optinose Us Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the XHANCE profile page.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Summary for 209022

Tradename:	XHANCE
Applicant:	Optinose Us Inc
Ingredient:	fluticasone propionate
Patents:	14
Formulation / Manufacturing:	see details

Pharmacology for NDA: 209022

Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Suppliers and Packaging for NDA: 209022

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022	NDA	OptiNose US, Inc.	71143-375	71143-375-01	1 BOTTLE in 1 CARTON (71143-375-01) / 120 SPRAY, METERED in 1 BOTTLE
XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022	NDA	OptiNose US, Inc.	71143-375	71143-375-98	1 BOTTLE in 1 CARTON (71143-375-98) / 28 SPRAY, METERED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SPRAY, METERED;NASAL			Strength	0.093MG
Approval Date:	Sep 18, 2017	TE:		RLD:	Yes
Patent:	⤷ Try a Trial	Patent Expiration:	Oct 20, 2034	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Try a Trial	Patent Expiration:	Jul 30, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
Patent:	⤷ Try a Trial	Patent Expiration:	Mar 6, 2027	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Expired US Patents for NDA 209022

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017	⤷ Try a Trial	⤷ Try a Trial
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017	⤷ Try a Trial	⤷ Try a Trial
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.